About Dry Eye
Dry eye is one of the most prevalent ocular diseases affecting 7% to 30% of the population depending on geography. It is often chronic and can worsen with some patients progressing to moderate to severe dry eye. Dry eye, in particular in its moderate to severe form, is a multifactorial disorder caused by inflammation of the ocular surface that results in symptoms of discomfort such as eye dryness, overall eye discomfort, stinging, burning, a gritty feeling or fluctuating blurry vision. Dry eye is most common in women and increases in prevalence with age.
Aim of MC2-03
Ciclosporin is widely used as a therapeutic agent in eye drops for treatment of patients with moderate to severe dry eye. However, current ciclosporin formulations have sub-optimal efficacy profiles and may cause stinging and burning in the eyes of patients.
Using PAD ™ Technology we have developed a new PAD ™ eye drop based formulation with ciclosporin designed to improve delivery of ciclosporin to ocular surface tissues. Our aim is to develop a low strength, once daily new drug with best-in-class efficacy and tolerability profile for treatment of a subset of patients suffering from moderate to severe dry eye. A solution intended to significantly improve daily quality of life of patients and provide an attractive value proposition to patients, physicians and societies.
Phase 2 (n=265) successfully completed in Q3 2018. Regulatory interaction in planning.
MC2-03 PAD ™ Eye Drop
Active ingredient: Ciclosporin
Indication: Moderate to severe dry eye